Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low‐dose‐rate brachytherapy alone or in combination with intensity‐modulated radiotherapy: An observational study using propensity score matching

Abstract

AbstractBackgroundIt is unclear whether a hydrogel spacer can improve quality of life (QOL) in patients undergoing low‐dose‐rate brachytherapy (LDR‐BT) alone or in combination with intensity‐modulated radiotherapy (IMRT).MethodsWe enrolled patients with prostate cancer who underwent LDR‐BT alone with (n = 186) or without (n = 348) a hydrogel spacer, or underwent LDR‐BT in combination with IMRT with (n = 70) or without (n = 217) a hydrogel spacer. QOL was evaluated using Expanded Prostate Cancer Index Composite (EPIC) questionnaires at baseline and 1, 3, 6, 12, and 24 months after implantation. The groups were compared using propensity score matching analysis.ResultsAmong patients who underwent LDR‐BT alone, there were no differences regarding changes in urinary, bowel, sexual, or hormonal domain scores between the spacer and no‐spacer groups; however, the dose at the bowel was significantly lower in the spacer group than in the no‐spacer group. Among patients who underwent LDR‐BT in combination with IMRT, there were no differences regarding changes in urinary, sexual, or hormonal domain scores between the spacer and no‐spacer groups. However, the changes in the bowel domain score were significantly lower in the spacer group than in the no‐spacer group (p < 0.001).ConclusionsA hydrogel spacer may not improve impaired urinary, bowel, or sexual QOL in patients undergoing LDR‐BT alone. However, in patients undergoing LDR‐BT in combination with IMRT, a hydrogel spacer can improve impaired bowel QOL but not sexual or urinary QOL.